Recruited for role by US President.Strategic and operational leadership of $9B US commercial structure including sales force of 3000 and more than 18 pharmaceutical brands, 5 of which are greater than $1B. Member of US Management Team. Selected by Wyeth Board for Global Leadership Program-only top 1% of employees attend.
-Led 5 year strategic planning process with US Management Team to evolve the commercial structure to be more customer focused, drive revenue growth and reduce operating expenses.Identified initiatives to deliver an additional $1B in revenue for four key launch/pre-launch brands: Prevenar 13V Adult and Pediatric (Vaccines) , Pristiq (Depression) , and Bapineuzumab (Alzheimer’s).
-Drove creation of an Executive Leadership Advisory Board to expand relationships with US thought leaders to successfully reposition Wyeth as a partner on critical US healthcare system issues. Members include notable leaders from: CMS, CVS/Caremark, United Healthcare, Harvard, Yale, Towers Perrin, Medicare, Cigna, Goodyear, FDA.
-Established e-Prescribing Team with SureScripts, Aetna and Humana to understand key customer drivers.
-Initiated move from activity based metrics to performance based metrics to enhance decision making and focus commercial performance on goals that drive business. Instituted regular review of key brand performance metrics and goals at monthly US management team meetings for high value brands including Enbrel, Effexor XR, Protonix, Premarin family, Pristiq and Xyntha.